Effect of granulocyte colony-stimulating factor on toxicities after CAR T cell therapy for lymphoma and myeloma
Abstract Chimeric antigen receptor T cells (CAR T) are groundbreaking therapies but may cause significant toxicities including cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and cytopenias. Granulocyte colony-stimulating factor (G-CSF) is often used...
Main Authors: | Kevin Charles Miller, Patrick Connor Johnson, Jeremy S. Abramson, Jacob D. Soumerai, Andrew J. Yee, Andrew R. Branagan, Elizabeth K. O’Donnell, Anna Saucier, Caron A. Jacobson, Matthew J. Frigault, Noopur S. Raje |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2022-11-01
|
Series: | Blood Cancer Journal |
Online Access: | https://doi.org/10.1038/s41408-022-00741-2 |
Similar Items
-
Lifestyle considerations in multiple myeloma
by: Yael N. Shapiro, et al.
Published: (2021-10-01) -
Treatment of Smoldering Multiple Myeloma: Ready for Prime Time?
by: E. Bridget Kim, et al.
Published: (2020-05-01) -
Clinical Grade “SNaPshot” Genetic Mutation Profiling in Multiple Myeloma
by: Elizabeth O'Donnell, et al.
Published: (2015-01-01) -
CAR-Based Approaches to Cutaneous T-Cell Lymphoma
by: Irene Scarfò, et al.
Published: (2019-04-01) -
Bone Disease in Multiple Myeloma: Biologic and Clinical Implications
by: Zachary S. Bernstein, et al.
Published: (2022-07-01)